Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 500
mg Divalproex Sodium (equivalent to 500 mg Valproic Acid) Extended Release Tablets with that
of Depakote® ER Tablets following a single oral dose (1 x 500 mg tablet) in healthy adult
subjects administered under fasting conditions.